Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States

Abstract

Considering a high prevalence region, prenatal screening for C. trachomatis resulted in increased expenditure, with a significant reduction in morbidity to woman-infant pairs. Screening programs are appropriate if the cost per individual is deemed acceptable to prevent the morbidity associated with C. trachomatis.